<unk>  is a tyrosine kinase inhibitor that is FDA approved for the treatment of metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.   Common adverse reactions include vision disorders, nausea, diarrhea, vomiting, constipation, edema, elevated transaminases, and fatigue.
Crizotinib
Nilotinib
Afatinib
Ruxolitinib
Neratinib
Axitinib
Dasatinib
Erdafitinib